Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: Bone. 2010 Aug 22;49(1):122–127. doi: 10.1016/j.bone.2010.08.011

Figure 3. IG9402 prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids and activates ERK survival signaling.

Figure 3

(A) The prevalence of apoptosis of osteoblasts, and cancellous and cortical osteocytes was determined by ISEL in lumbar vertebrae. (B) Maximum load of 6th lumbar vertebrae was measured by vertebral compression strength. GC: prednisolone, Aln: alendronate. * p<0.05 versus saline-placebo by two-way anova, n= 6–11 mice/group. (C) Mice (4/group) were given a single injection of saline, or 2.3 μM/kg/day alendronate or IG9402. Twenty four hours later mice were sacrificed and the 6th lumbar vertebrae were collected. Levels of phosphorylated and total ERK were determined by Western blotting and are expressed as fold change in phosphor-ERK/ERK over saline-treated mice. Each line corresponds to an individual animal. * p<0.05 versus saline by one-way anova.